Results overview: Found 5 records in 0.02 seconds.
Articles, 5 records found
Articles 5 records found  
1.
19 p, 2.6 MB A Novel Family of Lysosomotropic Tetracyclic Compounds for Treating Leukemia / Carbó, José María (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Cornet-Masana, Josep Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Cuesta-Casanovas, Laia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Delgado-Martínez, Jennifer (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Banús, Antònia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Clément-Demange, Lise (Leukos Biotech (Barcelona)) ; Serra, Carme (Institut de Química Avançada de Catalunya) ; Catena, Juanlo (Institut de Química Avançada de Catalunya) ; Llebaria, Amadeu (Institut de Química Avançada de Catalunya) ; Esteve Reyner, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Risueño, Ruth M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
In spite of the recent expansion of the therapeutic landscape for acute myeloid leukemia (AML), resistance mechanisms and relapsed disease still pose a serious barrier to achieve curation for most patients. [...]
2023 - 10.3390/cancers15061912
Cancers, Vol. 15 (march 2023)  
2.
18 p, 2.5 MB Prolactin receptor signaling induces acquisition of chemoresistance and reduces clonogenicity in acute myeloid leukemia / Cuesta-Casanovas, Laia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Delgado-Martínez, Jennifer (University of Barcelona. Faculty of Pharmacy) ; Cornet-Masana, Josep Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Carbó, José María (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Banús, Antònia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Guijarro, Francesca (Hospital Clínic i Provincial de Barcelona) ; Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ; Risueño, Ruth M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Development of precision medicine requires the identification of easily detectable and druggable biomarkers. Despite recent targeted drug approvals, prognosis of acute myeloid leukemia (AML) patients needs to be greatly improved, as relapse and refractory disease are still difficult to manage. [...]
2023 - 10.1186/s12935-023-02944-4
Cancer Cell International, Vol. 23 (may 2023)  
3.
12 p, 752.8 KB Lysosome-mediated chemoresistance in acute myeloid leukemia / Cuesta-Casanovas, Laia (Universitat Autònoma de Barcelona) ; Delgado-Martínez, Jennifer (Universitat de Barcelona) ; Cornet-Masana, Josep Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Carbó, José María (Leukos Biotech) ; Clément-Demange, Lise (Leukos Biotech (Barcelona)) ; Risueño, Ruth M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Despite the outstanding advances in understanding the biology underlying the pathophysiology of acute myeloid leukemia (AML) and the promising preclinical data published lastly, AML treatment still relies on a classic chemotherapy regimen largely unchanged for the past five decades. [...]
2022 - 10.20517/cdr.2021.122
Cancer Drug Resistance, Vol. 5 Núm. 1 (2022) , p. 233-244  
4.
6 p, 605.0 KB Histamine receptor 1 is expressed in leukaemic cells and affects differentiation sensitivity / Cornet-Masana, Josep Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Banús, Antònia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Cuesta-Casanovas, Laia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Carbó, José María (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Guijarro, F. (Hospital Clínic i Provincial de Barcelona) ; Torrente, M. Á. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Esteve Reyner, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Risueño, Ruth M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Despite the success of immunotherapy in several haematological neoplasms, the effectiveness in acute myeloid leukaemia (AML) is still controversial, partially due to the lack of knowledge regarding immune-related processes in this disease and similar neoplasias. [...]
2020 - 10.1111/jcmm.15930
Journal of Cellular and Molecular Medicine, Vol. 24 Núm. 22 (november 2020) , p. 13536-13541  
5.
14 p, 2.6 MB Dual lysosomal-mitochondrial targeting by antihistamines to eradicate leukaemic cells / Cornet-Masana, Josep Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Banús, Antònia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Carbó, José María (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Torrente, M. Á. (Hospital Clínic i Provincial de Barcelona) ; Guijarro, F. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Cuesta-Casanovas, Laia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Esteve Reyner, Jordi (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Risueño, Ruth M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Background: Despite great efforts to identify druggable molecular targets for AML, there remains an unmet need for more effective therapies. Methods: An in silico screening was performed using Connectivity Maps to identify FDA-approved drugs that may revert an early leukaemic transformation gene signature. [...]
2019 - 10.1016/j.ebiom.2019.08.021
EBioMedicine, Vol. 47 (september 2019) , p. 221-234  

See also: similar author names
1 Cornet-Masana, Josep M.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.